PUBLIC COMPANY
saveDAIICHI SANKYO
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- phase2A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- —Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
- phase2A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- phase3A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
- phase3Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- phase3Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
🐶 Hiring Signal
News
- RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winPlus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includ…endpoints · 10d ago
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 14d ago
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 17d ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 21d ago
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationAfter keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…fiercebiotech · 22d ago
- Eli Lilly tops new biopharma ranking on launch success, development speedFlush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…fiercebiotech · 23d ago
- GSK partner Hansoh reports another phase 3 win for priority ADCHansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.fiercebiotech · 23d ago
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.fiercebiotech · 24d ago
- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…fiercebiotech · 1mo ago
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.biopharma_dive · 1mo ago
comments(0)
5-min edit window · permanent after that